| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $33.5M | — | +34.1% |
| SG&A Expense | $8.5M | — | +23.8% |
| Operating Income | -$42.0M | — | -31.9% |
| Net Income | -$39.3M | — | -39.6% |
| EPS (Basic) | -$0.64 | — | -36.2% |
| EPS (Diluted) | -$0.64 | — | -36.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $85.0M | +9.8% | -15.7% |
| Current Assets | $394.6M | +48.7% | +21.6% |
| Total Assets | $412.0M | +45.8% | +20.0% |
| Current Liabilities | $19.3M | +6.4% | +35.2% |
| Total Liabilities | $24.5M | +4.4% | +22.7% |
| Stockholders' Equity | $387.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$32.6M | — | -27.9% |
| Capital Expenditures | $88K | — | +528.6% |
| Investing Cash Flow | -$120.2M | — | -475.5% |
| Financing Cash Flow | $160.4M | — | +7233.5% |
| Free Cash Flow | -$32.7M | — | -28.2% |
| +19.8% |